MBXNasdaqPharmaceutical PreparationsFiscal year ends December 31
MBX Biosciences, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$52.48+2.87 (+5.79%)
Close on Oct 19, 2026
- Market cap
- $2.50B
- P/E (TTM)
- –
- Dividend yield
- –
MBX Biosciences, Inc. cash flow statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, FY
- Gross margin
- –
- Operating margin
- –
- Net margin
- –
- Return on equity, FY2025
- -27.8%
Financial strength
- Current ratio
- 18.08
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 228.8%
Valuation
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 6.11
- Dividend yield
- –